Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study. Issue 7 (1st March 2019)

• Record Type: Journal Article
• Authors: Crielaard, Loes; Kavaliunas, Andrius; Ramanujam, Ryan; Olsson, Tomas; Hillert, Jan; Stridh, Pernilla; Kockum, Ingrid; Manouchehrinia, Ali
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 90:Issue 7(2019)
• Page Start: 761
• Page End: 767
• Publication Date: 2019-03-01
• Subjects: multiple sclerosis -- benign -- genotype data -- physical disability -- cognitive function -- self-reported impact -- risk of death -- Severity; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2018-319913
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objective: Benign multiple sclerosis (BMS) is often defined by the Expanded Disability Status Scale (EDSS) score of ≤3.0 after ≥15 years of disease duration. This classification's clinical relevance remains unclear as benign patients may suffer other impairments and advance towards a progressive course, prompting our objective to holistically investigate factors associated with BMS and its long-term prognosis. Methods: Benign cases were identified in the Swedish Multiple Sclerosis registry. Baseline clinical data, demographic features and influence of multiple sclerosis (MS) major risk alleles on likelihood of benign course were investigated. Physical disability (EDSS), cognitive function (Symbol Digit Modalities Test; SDMT) and self-reported and socioeconomic differences between benign and non-benign patients were evaluated using generalised estimation equations models. Results: 11222 patients (2420 benign/8802 non-benign) were included. Benign patients were more likely to be female and younger at MS onset, have fewer relapses within the first two and 5 years from onset and fully recover from the first relapse (p<0.001). No association between human leucocyte antigen ( HLA ) DRB1*15:01 carriership (OR: 0.97, 95% CI: 0.86 to 1.09) or HLA-A*02:01 lacking (OR: 0.99, 95% CI: 0.87 to 1.11) and benign/non-benign was found. Non-benign patients accumulated an extra 0.04 (95% CI 0.03 to 0.04, p<0.001) EDSS score/year, lost an extra 0.3 (95% CI − 0.39 to − 0.18, p<0.001) SDMT score/year and deteriorated faster in self-reported impact and socioeconomic measures (p<0.001). Conclusion: Patients with BMS have a better disease course as they progress more slowly at the group level in all respects. Lack of an association with major genetic risk factors indicates that MS course is most likely influenced by either environmental factor(s) or genetic factors outside the HLA region.